Users Online: 94
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 6  |  Issue : 2  |  Page : 47-50

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer

1 Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
2 Department of Oncology, Asian Institute of Oncology, Mumbai, Maharashtra, India
3 Department of Oncology, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India

Correspondence Address:
Sachin S Hingmire
Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Pune
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sajc.sajc_68_17

Rights and Permissions

Background: The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. However, such regimens of shorter duration trastuzumab therapy like FinHer, offered in view of economic constraints, may not be able to achieve globally comparable cure rates in early breast cancer especially with high-risk women with more than 3 lymph node positive. Methods and Material: Outcome of 21 patients with HER2 positive breast cancer was treated with short course trastuzumab combination chemotherapy in the adjuvant setting was studied. Results: Out of 21 patients 15 are alive and disease free with a follow up of up to 73 months (median follow up 42 months).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded208    
    Comments [Add]    

Recommend this journal